Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
LaunchHanmi Pharm. Co., Ltd. Announces Novel Obesity Drug HM17321 Designed to Augment Fat Loss While Increasing Lean Muscle Mass.
Nov 06, 2024
South KoreaBiotechnologyHealth CarePharmaceuticalpharmaceuticals
Product Description
Hanmi Pharm. Co., Ltd. has unveiled their promising novel obesity drug HM17321 at the 2024 ObesityWeek. This groundbreaking treatment is designed to reduce fat while enhancing lean muscle mass, addressing limitations present in current therapies.
Company Information
Company
Hanmi Pharmaceutical Ltd
Location
South Korea
About
Hanmi Pharmaceutical Co. Ltd. is a biopharmaceutical company engaged in the research, development, manufacture, and marketing of innovative medicines with a focus on metabolic disorders, oncology, and rare diseases. With several partnerships and a global presence, Hanmi aims to enhance healthcare through cutting-edge therapies. The company is noted for its investment in research and development and has a strong pipeline of products.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Hanmi Pharmaceutical Ltd ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.